Lippincott Journals Subscribers, use your username or email along with your password to log in.
Registered users can save articles, searches, and manage email alerts.
All registration fields are required.
Flash Player 9.0.0 is required for the Video Gallery.
Get Adobe Flash Player.
Colleague's E-mail is Invalid
Your message has been successfully sent to your colleague.
Menopause. 26(11):1277-1283, November 2019
Bisphosphonate is the first line agent for osteoporosis, although We have been worried about the occurrence of severe adverse event associated with bisphosphonate on oral cavity, osteonecrosis of the jaws (ONJ). Also, periodontal disease, especially is the important risk factor for ONJ. The aim of this study was to determine whether once-yearly zoledronic acid in combination with proper self-oral hygiene management can improve symptomatic periodontal disease compared with placebo. Our results suggest that bisphosphonate use in combination of proper self-oral hygiene management for osteoporosis patients can prevent symptomatic periodontal disease, resulting in the risk reduction of bisphosphonate-related ONJ.